PharmaEssentia Corporation
6446
Kedudukan dalam Saham
#1439
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Harga Saham
$36.89
Modal Pasaran
$15.25B
Perubahan (1 hari)
-1.28%
Perubahan (1 tahun)
144.12%
Negara
TW
Perdagangan PharmaEssentia Corporation (6446)
Kategori
Healthcare
Nisbah P/S bagi PharmaEssentia Corporation (6446)
Nisbah P/S pada October 2026 TTM: 23.96
Menurut laporan kewangan dan harga saham terkini PharmaEssentia Corporation, nisbah P/S semasa (TTM) ialah 23.96. Pada akhir 2023, nisbah P/S syarikat ialah 22.06.
Sejarah nisbah P/S untuk PharmaEssentia Corporation dari 2010 hingga 2026
Nisbah P/S pada akhir setiap tahun
| Tahun | Nisbah P/S | Ubah |
|---|---|---|
| 2026 (TTM) | 23.96 | 16.52% |
| 2024 | 20.56 | -6.80% |
| 2023 | 22.06 | -53.07% |
| 2022 | 47.01 | -58.98% |
| 2021 | 114.59 | 181.19% |
| 2020 | 40.75 | -46.81% |
| 2019 | 76.61 | -94.54% |
| 2018 | 1.40K | -81.75% |
| 2017 | 7.68K | 27.57% |
| 2016 | 6.02K | 95.48% |
| 2015 | 3.08K | 61.64% |
| 2014 | 1.91K | 276.50% |
| 2013 | 506.34 | -45.75% |
| 2012 | 933.30 | -41.98% |
| 2011 | 1.61K | 237.00% |
| 2010 | 477.29 | 0.00% |
Nisbah P/S untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/S | Perbezaan Nisbah P/S | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 7.06 | -70.54% |
IN
|
